文献速递外周动脉疾病

紫杉醇洗脱支架增加死亡率由病变长度驱动

Increased mortality with paclitaxel-eluting stents is driven by lesion length.
PubMed 文献 · J Vasc Surg · 2020-06-29

该回顾性研究纳入2011至2017年296例股腘动脉支架置入患者,比较紫杉醇洗脱支架(PES)与裸金属支架(BMS)的长期结局。中位随访23个月,总体2年全因死亡率无显著差异,但在TASC C/D病变中PES组2年全因死亡率显著更高(23.9% vs 5.1%,P=.05),校正后风险增加(aHR 2.3,95%CI 1.31-27,P=.02),且通畅性无优势。

要点

  • PES在TASC C/D股腘动脉病变中与2年全因死亡率显著升高相关。
  • 总体人群及TASC亚组中PES与BMS的通畅性和保肢率无差异。
  • 长病变需多枚长支架、紫杉醇剂量更大,可能驱动死亡率风险。

核心结论

  • 在真实世界中,PES使用与TASC C/D病变患者全因死亡风险增加约两倍相关。
  • PES与BMS在总体人群及按TASC II分层后的通畅性和保肢率无显著差异。

研究设计与样本

  • 回顾性病历综述,纳入2011年1月至2017年12月期间接受股腘动脉支架置入的296例患者。
  • 101例(34%)接受PES,195例(66%)接受BMS。
  • 中位随访时间23个月(四分位距7-40个月)。

主要发现

  • 总体2年全因死亡率PES组12% vs BMS组11.4%(P=.26)。
  • 2年保肢率90.7% vs 92%(P=.4),一期通畅率78.8% vs 81.1%(P=.62),一期辅助通畅率100% vs 96.5%(P=.4),二期通畅率100% vs 98.6%(P=.26)。
  • TASC C/D病变中PES组2年全因死亡率23.9% vs 5.1%(P=.05)。
  • 校正年龄及其他潜在混杂因素后,TASC C/D患者PES使用与全因死亡率显著增加相关(校正风险比2.3,95%CI 1.31-27,P=.02)。

临床怎么用

  • 对TASC C/D股腘动脉长病变患者选择PES时需权衡死亡风险,尤其需多枚长支架时。
  • PES在广泛病变中未显示通畅性优势,应个体化选择支架类型。

局限性

  • 回顾性设计,样本量有限,需更大规模研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Endovascular stenting has become the first-line treatment of symptomatic peripheral artery disease of the femoropopliteal axis (FPA). Several randomized clinical trials have reported that paclitaxel-eluting stents (PESs) significantly reduce the rates of restenosis. However, a meta-analysis investigating paclitaxel-coated devices in the FPA showed a significant increase in all-cause mortality after the use of PES. The aim of this study was to compare the long-term, real-world outcomes of bare-metal stents (BMSs) and PESs for treating FPA occlusive disease. METHODS: A retrospective review of the medical records of 296 patients who underwent FPA stenting between January 2011 and December 2017 was performed. Patients were grouped into BMS and PES groups. The primary end point was all-cause mortality. Secondary end points included limb salvage, primary patency, primary assisted patency, and secondary patency. A comparison between the two groups within TransAtlantic Inter-Society Consensus (TASC) II subgroups was also performed. RESULTS: Of the study cohort, 101 patients (34%) received PES, whereas 195 patients (66%) underwent BMS placement. Median follow-up time was 23 months (interquartile range, 7-40 months). The 2-year all-cause mortality estimates were 12% for the PES group compared with 11.4% for the BMS group (P = .26). There were no differences in the 2-year limb salvage (90.7% vs 92%; P = .4), primary patency (78.8% vs 81.1%; P = .62), primary assisted patency (100% vs 96.5%; P = .4), and secondary patency (100% vs 98.6%; P = .26) between the PES and the BMS groups, respectively (all P > .05). These findings persisted when patients were stratified by TASC II lesions. Among patients with TASC C and D lesions, the use of PES was associated with significantly higher 2-year all-cause mortality (23.9% vs 5.1%; P = .05). After adjustment for age and other potential confounders, PES use was associated with significant increase in all-cause mortality (adjusted hazard ratio, 2.3; 95% confidence interval, 1.31-27 P = .02) in TASC C and D patients. CONCLUSIONS: Consistent with the meta-analysis of several randomized clinical trials, the use of PES in a real-world setting was associated with a twofold increase in the risk of death. However, these findings were seen only among patients with TASC C and D lesions, who required multiple longer stents and potentially larger paclitaxel dose. There was no advantage in terms of patency in PES vs BMS in this population with extensive disease. Further studies of larger populations are required.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Mathlouthi A, Yei KS, Naazie I, et al. Increased mortality with paclitaxel-eluting stents is driven by lesion length. J Vasc Surg. 2020. PMID: 32615286. doi:10.1016/j.jvs.2020.05.061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。